Roche shares jumped by over 4% this morning after the pharmaceuticals group reported positive results from clinical trials.
The Swiss-based firm said a phase III trial into its Hemlibra haemophilia treatment had met targets with no major side-effects.
Roche also reported good results from a study on a new treatment for advanced lung cancer, claiming the breakthrough could bring a new standard of care in the area.
While shares in Roche were boosted by the developments, the stock of rivals such as Shire and AstraZeneca lost 1% and 0.5% respectively, as investors factored in the prospect of increased competition in certain product areas.
Shire for instance is a major player in haemophilia treatments.